Plus Therapeutics, Inc. announced on June 24, 2025, a comprehensive restructuring of its $15 million equity financing, originally announced on March 4, 2025. This strategic move eliminates the potential issuance of up to 1.5 billion shares of common stock.
The restructuring is expected to significantly enhance shareholder value and position the company with a more straightforward equity capital structure. The company has also filed a request with the SEC to withdraw the related resale registration statement.
Key highlights of the restructuring include the cancellation of all Series A and Series B warrants issued in the March 2025 financing. Additionally, the company issued new common stock and new warrants to the investors, with the new warrants having a higher exercise price and a lower share coverage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.